10-Q: MariMed Reports Q2 2026 Results: Revenue Up, Net Loss Widens

MariMed Inc. filed its Q2 2026 10-Q, showing a 6.1% revenue increase to $41.9 million but a widening net loss to $3.6 million, alongside a significant tax benefit from the reclassification of cannabis under federal law.

Summary

• MariMed Inc. reported Q2 2026 results with total revenue of $41.9 million, a 6.1% increase year-over-year.
• The company experienced a net loss of $3.6 million for the quarter, compared to a net loss of $1.4 million in the prior year period.
• Cost of revenue increased by 9.0% to $25.7 million, leading to a slight decrease in gross margin to 38.7% from 40.3%.
• Operating expenses rose by 6.0% to $15.8 million, driven by increases in general and administrative costs and bad debt expense.
• A significant development was the potential impact of the DOJ's reclassification of cannabis, leading to a $786,000 reduction in income tax expense for the quarter.
• The company's cash position decreased to $8.4 million from $8.9 million at the end of the previous year.
• Total liabilities increased to $147.1 million from $137.8 million, with a notable increase in mortgages and notes payable.
• The company continues to manage its debt obligations, including a substantial CREM Loan and various promissory notes.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously neutral to slightly negative due to continued net losses, increased debt, and operational cost pressures, despite revenue growth and a positive development regarding Section 280E.

Positives

• Total revenue increased by 6.1% to $41.9 million for the three months ended June 30, 2026, compared to $39.5 million in the prior year.
• Product sales, both retail and wholesale, showed year-over-year growth.
• Retail sales increased by 4.0% to $23.2 million, and wholesale revenue grew by 8.1% to $18.5 million.
• The company recorded a $786,000 reduction in income tax expense due to the DOJ's reclassification of cannabis, which is expected to allow for full deduction of ordinary and necessary business expenses.
• Adjusted EBITDA remained strong at $3.9 million for the quarter, although down from $4.8 million in the prior year.
• The company has a customer loyalty program designed to drive repeat business.

Negatives

• Net loss attributable to common stockholders widened to $3.6 million from $1.4 million in the prior year's quarter.
• Gross margin decreased to 38.7% from 40.3% due to a higher increase in the cost of revenue compared to revenue growth.
• Operating expenses increased by 6.0% to $15.8 million, with general and administrative costs and bad debt expense showing notable increases.
• Total liabilities increased to $147.1 million from $137.8 million, with mortgages and notes payable increasing significantly.
• Cash and cash equivalents decreased to $8.4 million from $8.9 million.
• The company is disputing significant IRS tax liens totaling approximately $1 million for FSC and $6 million for the company itself.

Risks

• The cannabis industry is highly regulated, and many aspects of the Company's business involve substantial risk of liability.
• The Company is subject to ongoing business risks that affect the estimation process of the carrying value of assets, the recording of liabilities, and the possibility of various loss contingencies.
• The Company is disputing significant IRS tax liens, and an unfavorable outcome could materially impact its operations and financial position.
• The Company's operations are conducted in jurisdictions where cannabis remains illegal under United States Federal law, creating inherent risks.
• The Company's financial condition and results of operations could be materially impacted by changes in demand for its services and products, changes in law and its enforcement, and changes in the economic environment.
• The Company faces ongoing litigation and regulatory proceedings in the ordinary course of business.

Future Outlook

The company aims to increase product brand revenue by strengthening cultivation and processing, developing new products, broadening distribution, and expanding into new markets. Retail store revenue is targeted for increase through enhanced customer experience and footprint expansion. The company believes its current cash and future funding opportunities will be sufficient to meet anticipated cash needs for working capital and capital expenditures for at least the next twelve months.

Management Comments

• Management believes that Adjusted EBITDA, when reviewed in conjunction with Net income (loss), is a useful measure to assess the Company's performance and liquidity, as it provides meaningful operating results by excluding the effects of expenses that are not reflective of the Company's operating business performance.
• Management believes that investors and analysts benefit from considering Adjusted EBITDA in assessing our financial results and our ongoing business, as it allows for meaningful comparisons and analysis of trends in the business.
• Management believes that inflation has impacted us through increased costs of ingredients, nutrients and packaging.
• Management believes that its financial condition and results of its operations are not materially impacted by seasonal sales.

Industry Context

StockSavvy.ai notes that MariMed operates in the highly regulated and evolving cannabis industry. The recent DOJ reclassification of cannabis to Schedule III is a significant development that could materially reduce tax burdens (like Section 280E) for compliant businesses, potentially improving profitability across the sector. However, federal illegality still presents operational and financial complexities.

Comparison to Industry Standards

• MariMed's gross margin of 38.7% for Q2 2026 is within the typical range for multi-state cannabis operators, which can vary significantly based on market, product mix, and operational efficiency.
• The net loss reported is a common challenge for many cannabis companies due to high operating costs, regulatory burdens, and the impact of Section 280E (prior to the Schedule III reclassification).
• The company's focus on brand development and retail expansion aligns with industry trends where differentiation and direct-to-consumer sales are key growth drivers.
• The debt levels, while substantial, are not uncommon for cannabis operators that have relied on debt financing for expansion due to federal restrictions on traditional banking and equity markets.

Legal Proceedings

• The Company may become involved in litigation or regulatory proceedings in the ordinary course of its business.
• The Company faces claims and threatened claims from former employees alleging wrongful termination and other similar alleged wrongdoing, which the Company disputes and which are not material.
• In 2022, the Plan Administrator filed a complaint against MMH for alleged preferential transfers, which was settled in 2023 by reducing MMH's general unsecured claim to $15.5 million. MMH received liquidation distributions in Q3 2024 and Q4 2025.
• The Company is disputing IRS tax liens totaling approximately $1 million for FSC (2023-2024 tax periods) and approximately $6 million for the Company (2023 tax liability).

Related Party Transactions

• Lease of corporate offices from an entity with an investment interest by the CEO.
• Procurement of nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the COO's family.
• Royalty payments on the Bettys Eddies product line to an entity owned by the COO and Chief Commercial Officer.
• Distributions to the CEO from a majority-owned subsidiary.
• Distributions to the CEO and COO from Mari Holdings Metropolis, LLC.
• Outstanding accounts payable to a third-party company in which the CEO has a controlling interest.
• Outstanding payables to the CEO for amounts advanced to the Company for operating activities.
• Personal guarantees by the CEO on mortgages with Bank of New England and DSB.

Stakeholder Impact

• Shareholders: Continued net losses and increased liabilities may impact shareholder value. The potential tax benefits from the Schedule III reclassification could be a positive factor.
• Employees: Stable personnel expenses suggest no immediate large-scale layoffs, but operational pressures could lead to future adjustments.
• Creditors: Increased debt levels and outstanding liabilities require careful management to ensure repayment obligations are met.
• Suppliers: Continued procurement from related parties and general cost pressures may affect supplier relationships and terms.
• Customers: The company's focus on product quality and customer experience aims to maintain and grow its customer base.

Next Steps

• Continue to focus on executing the strategic growth plan, including increasing product brand revenue and retail store revenue.
• Strengthen cultivation and processing capabilities.
• Develop and launch innovative new products.
• Broaden distribution networks and expand into new markets.
• Drive additional and higher average transactions in existing stores.
• Expand dispensary footprint in current and new markets.
• Monitor guidance from the DOJ and IRS regarding the impact of the Schedule III reclassification on tax provisions.
• Continue to dispute IRS tax liens.

Key Dates

Recommendation

While revenue growth is positive and the Schedule III reclassification offers a potential tax benefit, the widening net loss, increased debt, and ongoing tax disputes present significant headwinds. The company's ability to manage costs and leverage the tax changes will be critical. A 'hold' recommendation reflects a balance between these positive and negative factors, pending clearer signs of sustained profitability and debt reduction.

Keywords

cannabis, multi-state operator, revenue, net loss, operating expenses, Adjusted EBITDA, tax, debt